Product Code: A05262
The general anesthesia drug market was valued at $5,400.5 million in 2021, and is projected to reach $7,736.3 million by 2031, registering a CAGR of 3.5% from 2022 to 2031. General anesthesia is a combination of medication which causes sleep-like state before a surgery or other medical procedure. Under general anesthesia patient does not feel pain because patient is completely in unconscious state. General anesthesia is given with the combination of intravenous and inhalation anesthesia drugs. There are many equipment specifically designed for different surgical procedures. These include anesthetic vaporizer that is used as a vaporizing anesthetic; nasal oxygen set for delivering oxygen and others. Some intravenous drugs such as propofol, etomidate, and ketamine are intravenous sedative hypotonic agents which are given in general anesthesia. Sevoflurane and desflurane are inhalation general anesthesia drugs which are used during surgical procedure.
The general anesthesia drug market is majorly driven by increase in number of surgical procedures like hip and knee replacement surgery, cardiac surgery, general surgeries cancer surgeries, rise in number of geriatric population, increase in prevalence of osteoarthritis disease, and neurological disorder. Moreover increase in number of key players to formulate general anesthesia drug, propels the growth of the market. According to the rheumatology advisor, the annual number of total knee arthroplasty was predicted to increase by 56% from 2019 to 2020. The demand for general anesthesia increases due to an increase in the number of knee arthroplasty surgery procedures. The knee and hip replacement procedures are majorly conducted under general anesthesia. Increase in prevalence of chronic disease, such as cardiovascular disease, cancer, and others is one of the major factor that boosts the growth of the market. According to the Centers for disease control and prevention (CDC) approximately 659,000 population in the U.S. experienced death from heart disease each year. According to the same report in 2019, a total of 360,900 people died due to coronary heart disease. Every year in the U.S. approximately 805,000 population are diagnosed with heart attack among which 605,000 experienced their first heart attack. This factor upsurges the need for heart surgery, which further increases the need for general anesthesia.
On the contrary, risk associated with general anesthesia such as allergic reaction, nausea, and vomiting is anticipated to hinder the market growth during the forecast period. Advancement in R&D activities in general anesthesia in pharmaceutical and biotechnology sector propels the growth of the market. Rise in funding from government or non-government organization to provide surgical resources, encourages many key players to enter emerging markets, thus offering a lucrative growth opportunity in the general anesthesia drug market.
The general anesthesia drug market is segmented into type of drug, route of administration, surgery type, end user, and region. By type of drug, the market is categorized into propofol, sevoflurane, desflurane and other. Further the others segment is studied under ketamine, thiopental, methohexital, etomidate, isoflurane, and fospropofol. By route of administration, the market is bifurcated into intravenous and inhalation. By surgery, the market is divided into knee & hip replacements, heart surgeries, cancer surgery, and general surgery. By end user the market is classified into hospital and ambulatory surgical centers. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Some of the major companies that operate in the general anesthesia drug market are AbbVie, AstraZeneca, Avet Pharmaceuticals Inc. B. Braun Melsungen, Baxter International Inc., Fresenius SE & Co. KGaA, Hikma Pharmaceuticals PLC, PAION AG, Abbott, and Pfizer.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the general anesthesia drugs market analysis from 2021 to 2031 to identify the prevailing general anesthesia drugs market opportunity.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the general anesthesia drugs market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global general anesthesia drugs market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By TYPE OF DRUGS
- Propofol
- Sevoflurane
- Desflurane
- Others
By ROUTE OF ADMNISTRATION
By SURGERY TYPE
- Knee and hip replacements
- Heart surgeries
- Cancer surgery
- General surgery
By END USER
- Hospital
- Ambulatory surgical centers
By Region
- North America
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- B. Braun Melsungen
- Baxter International Inc.
- Fresenius SE and Co. KGaA
- Hikma Pharmaceuticals plc
- Paion AG
- Pfizer Inc.
- Abbott Laboratories
- Abbvie Inc
- AstraZeneca plc
- Avet Pharmaceuticals Inc
TABLE OF CONTENTS
CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter's five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: GENERAL ANESTHESIA DRUGS MARKET, BY TYPE OF DRUGS
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Propofol
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.3 Sevoflurane
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- 4.4 Desflurane
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country
- 4.5 Others
- 4.5.1 Key market trends, growth factors and opportunities
- 4.5.2 Market size and forecast, by region
- 4.5.3 Market analysis by country
CHAPTER 5: GENERAL ANESTHESIA DRUGS MARKET, BY ROUTE OF ADMNISTRATION
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Intravenous
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.3 Inhalation
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
CHAPTER 6: GENERAL ANESTHESIA DRUGS MARKET, BY SURGERY TYPE
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 Knee and hip replacements
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
- 6.3 Heart surgeries
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
- 6.4 Cancer surgery
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market analysis by country
- 6.5 General surgery
- 6.5.1 Key market trends, growth factors and opportunities
- 6.5.2 Market size and forecast, by region
- 6.5.3 Market analysis by country
CHAPTER 7: GENERAL ANESTHESIA DRUGS MARKET, BY END USER
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 Hospital
- 7.2.1 Key market trends, growth factors and opportunities
- 7.2.2 Market size and forecast, by region
- 7.2.3 Market analysis by country
- 7.3 Ambulatory surgical centers
- 7.3.1 Key market trends, growth factors and opportunities
- 7.3.2 Market size and forecast, by region
- 7.3.3 Market analysis by country
CHAPTER 8: GENERAL ANESTHESIA DRUGS MARKET, BY REGION
- 8.1 Overview
- 8.1.1 Market size and forecast
- 8.2 North America
- 8.2.1 Key trends and opportunities
- 8.2.2 North America Market size and forecast, by TYPE OF DRUGS
- 8.2.3 North America Market size and forecast, by ROUTE OF ADMNISTRATION
- 8.2.4 North America Market size and forecast, by SURGERY TYPE
- 8.2.5 North America Market size and forecast, by END USER
- 8.2.6 North America Market size and forecast, by country
- 8.2.6.1 U.S.
- 8.2.6.1.1 Market size and forecast, by TYPE OF DRUGS
- 8.2.6.1.2 Market size and forecast, by ROUTE OF ADMNISTRATION
- 8.2.6.1.3 Market size and forecast, by SURGERY TYPE
- 8.2.6.1.4 Market size and forecast, by END USER
- 8.2.6.2 Canada
- 8.2.6.2.1 Market size and forecast, by TYPE OF DRUGS
- 8.2.6.2.2 Market size and forecast, by ROUTE OF ADMNISTRATION
- 8.2.6.2.3 Market size and forecast, by SURGERY TYPE
- 8.2.6.2.4 Market size and forecast, by END USER
- 8.2.6.3 Mexico
- 8.2.6.3.1 Market size and forecast, by TYPE OF DRUGS
- 8.2.6.3.2 Market size and forecast, by ROUTE OF ADMNISTRATION
- 8.2.6.3.3 Market size and forecast, by SURGERY TYPE
- 8.2.6.3.4 Market size and forecast, by END USER
- 8.3 Europe
- 8.3.1 Key trends and opportunities
- 8.3.2 Europe Market size and forecast, by TYPE OF DRUGS
- 8.3.3 Europe Market size and forecast, by ROUTE OF ADMNISTRATION
- 8.3.4 Europe Market size and forecast, by SURGERY TYPE
- 8.3.5 Europe Market size and forecast, by END USER
- 8.3.6 Europe Market size and forecast, by country
- 8.3.6.1 Germany
- 8.3.6.1.1 Market size and forecast, by TYPE OF DRUGS
- 8.3.6.1.2 Market size and forecast, by ROUTE OF ADMNISTRATION
- 8.3.6.1.3 Market size and forecast, by SURGERY TYPE
- 8.3.6.1.4 Market size and forecast, by END USER
- 8.3.6.2 France
- 8.3.6.2.1 Market size and forecast, by TYPE OF DRUGS
- 8.3.6.2.2 Market size and forecast, by ROUTE OF ADMNISTRATION
- 8.3.6.2.3 Market size and forecast, by SURGERY TYPE
- 8.3.6.2.4 Market size and forecast, by END USER
- 8.3.6.3 U.K.
- 8.3.6.3.1 Market size and forecast, by TYPE OF DRUGS
- 8.3.6.3.2 Market size and forecast, by ROUTE OF ADMNISTRATION
- 8.3.6.3.3 Market size and forecast, by SURGERY TYPE
- 8.3.6.3.4 Market size and forecast, by END USER
- 8.3.6.4 Italy
- 8.3.6.4.1 Market size and forecast, by TYPE OF DRUGS
- 8.3.6.4.2 Market size and forecast, by ROUTE OF ADMNISTRATION
- 8.3.6.4.3 Market size and forecast, by SURGERY TYPE
- 8.3.6.4.4 Market size and forecast, by END USER
- 8.3.6.5 Spain
- 8.3.6.5.1 Market size and forecast, by TYPE OF DRUGS
- 8.3.6.5.2 Market size and forecast, by ROUTE OF ADMNISTRATION
- 8.3.6.5.3 Market size and forecast, by SURGERY TYPE
- 8.3.6.5.4 Market size and forecast, by END USER
- 8.3.6.6 Rest of Europe
- 8.3.6.6.1 Market size and forecast, by TYPE OF DRUGS
- 8.3.6.6.2 Market size and forecast, by ROUTE OF ADMNISTRATION
- 8.3.6.6.3 Market size and forecast, by SURGERY TYPE
- 8.3.6.6.4 Market size and forecast, by END USER
- 8.4 Asia-Pacific
- 8.4.1 Key trends and opportunities
- 8.4.2 Asia-Pacific Market size and forecast, by TYPE OF DRUGS
- 8.4.3 Asia-Pacific Market size and forecast, by ROUTE OF ADMNISTRATION
- 8.4.4 Asia-Pacific Market size and forecast, by SURGERY TYPE
- 8.4.5 Asia-Pacific Market size and forecast, by END USER
- 8.4.6 Asia-Pacific Market size and forecast, by country
- 8.4.6.1 China
- 8.4.6.1.1 Market size and forecast, by TYPE OF DRUGS
- 8.4.6.1.2 Market size and forecast, by ROUTE OF ADMNISTRATION
- 8.4.6.1.3 Market size and forecast, by SURGERY TYPE
- 8.4.6.1.4 Market size and forecast, by END USER
- 8.4.6.2 Japan
- 8.4.6.2.1 Market size and forecast, by TYPE OF DRUGS
- 8.4.6.2.2 Market size and forecast, by ROUTE OF ADMNISTRATION
- 8.4.6.2.3 Market size and forecast, by SURGERY TYPE
- 8.4.6.2.4 Market size and forecast, by END USER
- 8.4.6.3 India
- 8.4.6.3.1 Market size and forecast, by TYPE OF DRUGS
- 8.4.6.3.2 Market size and forecast, by ROUTE OF ADMNISTRATION
- 8.4.6.3.3 Market size and forecast, by SURGERY TYPE
- 8.4.6.3.4 Market size and forecast, by END USER
- 8.4.6.4 Australia
- 8.4.6.4.1 Market size and forecast, by TYPE OF DRUGS
- 8.4.6.4.2 Market size and forecast, by ROUTE OF ADMNISTRATION
- 8.4.6.4.3 Market size and forecast, by SURGERY TYPE
- 8.4.6.4.4 Market size and forecast, by END USER
- 8.4.6.5 South Korea
- 8.4.6.5.1 Market size and forecast, by TYPE OF DRUGS
- 8.4.6.5.2 Market size and forecast, by ROUTE OF ADMNISTRATION
- 8.4.6.5.3 Market size and forecast, by SURGERY TYPE
- 8.4.6.5.4 Market size and forecast, by END USER
- 8.4.6.6 Rest of Asia-Pacific
- 8.4.6.6.1 Market size and forecast, by TYPE OF DRUGS
- 8.4.6.6.2 Market size and forecast, by ROUTE OF ADMNISTRATION
- 8.4.6.6.3 Market size and forecast, by SURGERY TYPE
- 8.4.6.6.4 Market size and forecast, by END USER
- 8.5 LAMEA
- 8.5.1 Key trends and opportunities
- 8.5.2 LAMEA Market size and forecast, by TYPE OF DRUGS
- 8.5.3 LAMEA Market size and forecast, by ROUTE OF ADMNISTRATION
- 8.5.4 LAMEA Market size and forecast, by SURGERY TYPE
- 8.5.5 LAMEA Market size and forecast, by END USER
- 8.5.6 LAMEA Market size and forecast, by country
- 8.5.6.1 Brazil
- 8.5.6.1.1 Market size and forecast, by TYPE OF DRUGS
- 8.5.6.1.2 Market size and forecast, by ROUTE OF ADMNISTRATION
- 8.5.6.1.3 Market size and forecast, by SURGERY TYPE
- 8.5.6.1.4 Market size and forecast, by END USER
- 8.5.6.2 Saudi Arabia
- 8.5.6.2.1 Market size and forecast, by TYPE OF DRUGS
- 8.5.6.2.2 Market size and forecast, by ROUTE OF ADMNISTRATION
- 8.5.6.2.3 Market size and forecast, by SURGERY TYPE
- 8.5.6.2.4 Market size and forecast, by END USER
- 8.5.6.3 South Africa
- 8.5.6.3.1 Market size and forecast, by TYPE OF DRUGS
- 8.5.6.3.2 Market size and forecast, by ROUTE OF ADMNISTRATION
- 8.5.6.3.3 Market size and forecast, by SURGERY TYPE
- 8.5.6.3.4 Market size and forecast, by END USER
- 8.5.6.4 Rest of LAMEA
- 8.5.6.4.1 Market size and forecast, by TYPE OF DRUGS
- 8.5.6.4.2 Market size and forecast, by ROUTE OF ADMNISTRATION
- 8.5.6.4.3 Market size and forecast, by SURGERY TYPE
- 8.5.6.4.4 Market size and forecast, by END USER
CHAPTER 9: COMPANY LANDSCAPE
- 9.1. Introduction
- 9.2. Top winning strategies
- 9.3. Product Mapping of Top 10 Player
- 9.4. Competitive Dashboard
- 9.5. Competitive Heatmap
- 9.6. Key developments
CHAPTER 10: COMPANY PROFILES
- 10.1 B. Braun Melsungen
- 10.1.1 Company overview
- 10.1.2 Company snapshot
- 10.1.3 Operating business segments
- 10.1.4 Product portfolio
- 10.1.5 Business performance
- 10.1.6 Key strategic moves and developments
- 10.2 Baxter International Inc.
- 10.2.1 Company overview
- 10.2.2 Company snapshot
- 10.2.3 Operating business segments
- 10.2.4 Product portfolio
- 10.2.5 Business performance
- 10.2.6 Key strategic moves and developments
- 10.3 Fresenius SE and Co. KGaA
- 10.3.1 Company overview
- 10.3.2 Company snapshot
- 10.3.3 Operating business segments
- 10.3.4 Product portfolio
- 10.3.5 Business performance
- 10.3.6 Key strategic moves and developments
- 10.4 Hikma Pharmaceuticals plc
- 10.4.1 Company overview
- 10.4.2 Company snapshot
- 10.4.3 Operating business segments
- 10.4.4 Product portfolio
- 10.4.5 Business performance
- 10.4.6 Key strategic moves and developments
- 10.5 Paion AG
- 10.5.1 Company overview
- 10.5.2 Company snapshot
- 10.5.3 Operating business segments
- 10.5.4 Product portfolio
- 10.5.5 Business performance
- 10.5.6 Key strategic moves and developments
- 10.6 Pfizer Inc.
- 10.6.1 Company overview
- 10.6.2 Company snapshot
- 10.6.3 Operating business segments
- 10.6.4 Product portfolio
- 10.6.5 Business performance
- 10.6.6 Key strategic moves and developments
- 10.7 Abbott Laboratories
- 10.7.1 Company overview
- 10.7.2 Company snapshot
- 10.7.3 Operating business segments
- 10.7.4 Product portfolio
- 10.7.5 Business performance
- 10.7.6 Key strategic moves and developments
- 10.8 Abbvie Inc
- 10.8.1 Company overview
- 10.8.2 Company snapshot
- 10.8.3 Operating business segments
- 10.8.4 Product portfolio
- 10.8.5 Business performance
- 10.8.6 Key strategic moves and developments
- 10.9 AstraZeneca plc
- 10.9.1 Company overview
- 10.9.2 Company snapshot
- 10.9.3 Operating business segments
- 10.9.4 Product portfolio
- 10.9.5 Business performance
- 10.9.6 Key strategic moves and developments
- 10.10 Avet Pharmaceuticals Inc
- 10.10.1 Company overview
- 10.10.2 Company snapshot
- 10.10.3 Operating business segments
- 10.10.4 Product portfolio
- 10.10.5 Business performance
- 10.10.6 Key strategic moves and developments